Q-omics provides the consensus-scored HIPK2 profile across patient tissues and cancer cell-line models. HIPK2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HIPK2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HIPK2 RNA expression shows 19,359 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where HIPK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIPK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIPK2 survival associations across molecular data types. HIPK2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIPK2 RNA expression–survival associations across cancer types. High HIPK2 expression shows unfavorable associations in CESC, LUSC and BLCA, but favorable associations in KIRC, LGG and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HIPK2 RNA expression.
This table summarizes HIPK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for HIPK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIPK2 shows lower tumor expression in BRCA, KIRP and LUSC and higher tumor expression in KIRC, LIHC and PRAD. The KIRC box plot shows higher HIPK2 RNA expression in tumor versus normal tissue (log2 FC = +0.709, t-test p < 0.001).
This table shows molecular features associated with HIPK2 in patient tissues and cancer cell lines. In patient samples, HIPK2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, HIPK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
